Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

C4 THERAPEUTICS, INC.

(CCCC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Certain Stock Options of C4 Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 15-SEP-2021.

09/15/2021 EDT

Certain Stock Options of C4 Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 15-SEP-2021. These Stock Options will be under lockup for 91 days starting from 16-JUN-2021 to 15-SEP-2021. Details: The executive officers, directors have entered into lock-up agreements with the underwriters prior to the commencement of this offering pursuant to which each lock-up party, with limited exceptions, for a period of 90 days after the date of this prospectus may not without the prior written consent of J.P. Morgan Securities LLC, Jefferies LLC and Evercore Group L.L.C.: (i) sell or offer to sell any shares of common stock or Related Securities by such person or their family member, (ii) enter into any swap, (iii) make any demand for, or exercise any right with respect to, the registration under the Securities Act of the offer and sale of any shares of common stock or Related Securities, or cause to be filed a registration statement, prospectus or prospectus supplement (or an amendment or supplement thereto) with respect to any such registration, or (iv) publicly announce an intention to do any of the foregoing.


ę S&P Capital IQ 2021
All news about C4 THERAPEUTICS, INC.
10/14C4 THERAPEUTICS : SVB Leerink Starts C4 Therapeutics at Outperform with $67 Price Target
MT
10/05INSIDER SELL : C4 Therapeutics
MT
09/30C4 THERAPEUTICS : Stifel Starts C4 Therapeutics at Hold With $45 Price Target
MT
09/24INSIDER SELL : C4 Therapeutics
MT
09/22INSIDER SELL : C4 Therapeutics
MT
09/17INSIDER SELL : C4 Therapeutics
MT
09/15Certain Common Stock of C4 Therapeutics, Inc. are subject to a Lock-Up Agreement Ending..
CI
09/15Certain Stock Options of C4 Therapeutics, Inc. are subject to a Lock-Up Agreement Endin..
CI
09/14INSIDER SELL : C4 Therapeutics
MT
08/12C4 THERAPEUTICS' : Q2 Loss Narrows, Revenue Grows; Secures Orphan Drug Designation for Mul..
MT
More news
Analyst Recommendations on C4 THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 31,8 M - -
Net income 2021 -103 M - -
Net cash 2021 378 M - -
P/E ratio 2021 -20,1x
Yield 2021 -
Capitalization 2 176 M 2 176 M -
EV / Sales 2021 56,5x
EV / Sales 2022 61,9x
Nbr of Employees 99
Free-Float 87,1%
Chart C4 THERAPEUTICS, INC.
Duration : Period :
C4 Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends C4 THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 44,91 $
Average target price 60,00 $
Spread / Average Target 33,6%
EPS Revisions
Managers and Directors
Andrew J. Hirsch President, Chief Executive Officer & Director
Lauren White Treasurer, Chief Financial & Accounting Officer
Marc A. Cohen Executive Chairman
Adam S. Crystal Chief Medical Officer
Stewart Fisher Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
C4 THERAPEUTICS, INC.33.29%2 140
MODERNA, INC.230.95%141 099
LONZA GROUP AG31.93%60 646
IQVIA HOLDINGS INC.42.93%49 145
SEAGEN INC.1.46%31 933
CELLTRION, INC.-38.02%25 328